Latest News Archive

Please select Category, Year, and then Month to display items

COVID-19 vaccinations open to people over the age of 18

20 August 2021 | Story Department of Communication and Marketing

Dear Student,

As from today (20 August 2021), all people 18 years and older are eligible to be vaccinated against COVID-19. Register on the COVID-19 Vaccination Programme registration portal to get the vaccine.

Individuals aged 18 and older can get vaccinated at sites across the country – including the Universitas Academic Hospital in Bloemfontein and retail stores such as Clicks and Dischem.

Remember, you can walk into any vaccination site to register and vaccinate.

Here is a list of registered vaccination sites closest to the University of the Free State campuses:

- Boikhuco Old Age Home – Bloemfontein (Mangaung)

- MUCPP Community Health Centre in Rocklands – Bloemfontein (Mangaung)x

- Pelonomi Hospital – Bloemfontein (Mangaung)

- Standard Bank Building – Bloemfontein (Mangaung)

- Universitas Academic Hospital – Bloemfontein (Mangaung)

- Botshabelo Hospital – Botshabelo (Mangaung)

- Seemahale Secondary School – Botshabelo (Mangaung)

- Dr JS Moroka Hospital – Thaba Nchu (Mangaung)

- Dihlabeng Regional Hospital – Bethlehem, Dihlabeng (Thabo Mofutsanyana)

- Thabo Thokoza Secondary School – Dihlabeng (Thabo Mofutsanyana)

- Thekolohelong Old Age Home – Maluti-A-Phofung (Thabo Mofutsanyana)

- Senorita Nthlabathi District Hospital – Mantsopa (Thabo Mofutsanyana)

- Nketoana District Hospital – Nketoana (Thabo Mofutsanyana)

- Phumelela District Hospital – Phumelela (Thabo Mofutsanyana)

Vaccines are an important part of stopping the spread of COVID-19. Vaccines reduce the risk of getting a disease by working with your body to build protection.

Need more information on vaccines? Read our COVID-19 Vaccine Information booklet here.

Visit the UFS COVID-19 webpage for updated information.

News Archive

Nano research at the UFS opens door to smart drugs

2011-06-27

Prof. Lodewyk Kock, outstanding professor in our Department of Microbial, Biochemical and Food Biotechnology

Novel antifungal, anticancer and anti-malaria drugs that have been identified in the research of Prof. Lodewyk Kock, outstanding professor in the Department of Microbial, Biochemical and Food Biotechnology at our university, will be disclosed later this year at major international conferences in Asia, Europe and the USA. Prof. Kock will be the keynote speaker at these conferences.

His presentations will be based on the department’s discovery of yeast assays linked to a new nanotechnology for medicine. The assays were recently discovered by his group and can be applied in the development of novel antifungal, anticancer and anti-malaria drugs.

Prof. Kock’s focused research at the university, which now also includes his novel nanotechnology for Biology, began in 1982 in collaboration with Prof. Pieter van Wyk (Centre for Microscopy). He recently collaborated with Prof. Hendrik Swart (Department of Physics).

Prof. Kock says the development of novel anti-malaria drugs in particular is getting attention across the world due to the high rates of morbidity and mortality caused by the disease worldwide. Approximately 225 million people are infected annually and about a million (many in Africa) die each year. “Many potential smart drugs have been identified with this research and should now be tested further,” says Kock.

These new drugs will be disclosed during Prof. Kock’s keynote addresses at the International Conference and Exhibition on Pharmaceutical Regulatory Affairs in Baltimore, USA, from 6 to 7 September 2011, the Medichem 2011 in Beijing, China from 9 to 11 August 2011 and the XVI Congress of European Mycologists in Greece, from 19 to 23 September 2011.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept